Profit Explosion $ORMP: +40% in 1 week
In April our algorithm picked up a significant insider buy in Oramed Pharmaceuticals Inc.: Li Xiaopeng, a Director of the company, bought 52,814 shares worth 334,313 dollars that day. The price? $6.33. Today ORMP is listed at $8.48… This represents a gain of +32% from the April 19 alert. If you had sold it on April 26, just 1 week (!!!) after the insider trading alert, you would have a quick profit of 40% in your pocket as you can see on the screenshot below.
A +40% gain…Li Xiaopeng knows what he is doing and he timed his buy perfectly! The reason why the stock went up and is still going up further is because ORMP received patents in multiple continents for their new drug. I received a few e-mails in my personal mailbox about the ORMP insider buying alert and some subscribers made a lot of money here. Although I would advise everyone to stay methodical, I am happy that many made huge financial strides on this trade (and that some take the time to write these delightful notes)!
More information on Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.